Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

Petra J Woestenberg; Audrey J King; Birgit H B Van Benthem; Suzan Leussink; Marianne A B Van der Sande; Christian J P A Hoebe; Johannes A Bogaards; Medical Microbiological Laboratories and the Public Health Services

doi:10.1093/infdis/jiz187

Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

Petra J Woestenberg^*, Audrey J King, Birgit H B Van Benthem, Suzan Leussink, Marianne A B Van der Sande, Christian J P A Hoebe, Johannes A Bogaards, Medical Microbiological Laboratories and the Public Health Services

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Web of Science)

Abstract

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Original language	English
Pages (from-to)	1280-1285
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	221
Issue number	8
DOIs	https://doi.org/10.1093/infdis/jiz187
Publication status	Published - 15 Apr 2020

Keywords

Human papillomavirus (HPV)
human papillomavirus vaccine
vaccine effectiveness
public health
anal cancer
HPV VACCINE
WOMEN
PREVALENCE
RISK

Access to Document

10.1093/infdis/jiz187

Cite this

Woestenberg, P. J., King, A. J., Van Benthem, B. H. B., Leussink, S., Van der Sande, M. A. B., Hoebe, C. J. P. A., Bogaards, J. A., & Medical Microbiological Laboratories and the Public Health Services (2020). Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. Journal of Infectious Diseases, 221(8), 1280-1285. https://doi.org/10.1093/infdis/jiz187

@article{5ae08a0b582a4d19908e2689a7bd336b,

title = "Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands",

abstract = "Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.",

keywords = "Human papillomavirus (HPV), human papillomavirus vaccine, vaccine effectiveness, public health, anal cancer, HPV VACCINE, WOMEN, PREVALENCE, RISK",

author = "Woestenberg, {Petra J} and King, {Audrey J} and {Van Benthem}, {Birgit H B} and Suzan Leussink and {Van der Sande}, {Marianne A B} and Hoebe, {Christian J P A} and Bogaards, {Johannes A} and {Medical Microbiological Laboratories and the Public Health Services}",

note = "{\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",

year = "2020",

month = apr,

day = "15",

doi = "10.1093/infdis/jiz187",

language = "English",

volume = "221",

pages = "1280--1285",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "8",

}

Woestenberg, PJ, King, AJ, Van Benthem, BHB, Leussink, S, Van der Sande, MAB, Hoebe, CJPA, Bogaards, JA & Medical Microbiological Laboratories and the Public Health Services 2020, 'Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands', Journal of Infectious Diseases, vol. 221, no. 8, pp. 1280-1285. https://doi.org/10.1093/infdis/jiz187

Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. / Woestenberg, Petra J; King, Audrey J; Van Benthem, Birgit H B et al.

In: Journal of Infectious Diseases, Vol. 221, No. 8, 15.04.2020, p. 1280-1285.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

AU - Woestenberg, Petra J

AU - King, Audrey J

AU - Van Benthem, Birgit H B

AU - Leussink, Suzan

AU - Van der Sande, Marianne A B

AU - Hoebe, Christian J P A

AU - Bogaards, Johannes A

AU - Medical Microbiological Laboratories and the Public Health Services

PY - 2020/4/15

Y1 - 2020/4/15

N2 - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

AB - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

KW - Human papillomavirus (HPV)

KW - human papillomavirus vaccine

KW - vaccine effectiveness

KW - public health

KW - anal cancer

KW - HPV VACCINE

KW - WOMEN

KW - PREVALENCE

KW - RISK

U2 - 10.1093/infdis/jiz187

DO - 10.1093/infdis/jiz187

M3 - Article

C2 - 31100134

SN - 0022-1899

VL - 221

SP - 1280

EP - 1285

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 8

ER -